Drug Trial Radar · NCT06979609
Secondary Prevention of Clostridioides Difficile Using Vancomycin
Last checked: Nov 20, 2026Latest source record: Jun 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Nov 1, 2025
Primary completion
Oct 1, 2028
Study completion Oct 1, 2029
Sponsor
- Lead sponsor
- McGill University Health Centre/Research Institute of the McGill University Health CentreAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Re-exposure to systemic antibiotics (i.e., antibiotics absorbed into the bloodstream) is common after a Clostridioides difficile infection (CDI) and is the strongest risk factor for a recurrent episode. Oral vancomycin to prevent a recurrence during antibiotic re-exposure may reduce this risk but the data supporting this practice are limited. The aim of this trial is: 1\) Does oral vancomycin prophylaxis prevent CDI recurrences in patients with recent CDI (within 120 days) and who are re-exposed to systemic antibiotics? The trial will compare oral vancomycin to placebo. Participants will: * Take the study drug (either vancomycin or placebo) twice daily for the duration of systemic antibiotics plus once daily for 7 days after completion of systemic antibiotics. * Attend an in-person or over the phone follow-up at day 56 * Respond to weekly electronic questionnaires
Conditions
- Clostridioides Difficile Infection
- Clostridioides Difficile Infection Recurrence
- Clostridoides Difficile Associated Disease
Interventions
Oral Vancomycin ProphylaxisDrug
125mg PO BID for the duration of antibiotic re-exposure + 125mg PO QD for 7 days
PlaceboDrug
2 capsules PO BID for the duration of antibiotic re-exposure + 1 capsule PO QD x 7 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- CDI RecurrenceTime frame: 56 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
McGill University Health Centre
Montreal, Quebec, Canada · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.